ELEKTA PROVIDES VMAT AND RADIOSURGERY SOLUTIONS FOR NEW JERSEY HEALTH SYSTEM

ELEKTA PROVIDES VMAT AND RADIOSURGERY SOLUTIONS FOR NEW JERSEY HEALTH SYSTEM

Press Release 
Stockholm, Sweden, June 18, 2009

CentraState Medical Center (Freehold, New Jersey) has purchased two new
state-of-the-art Elekta radiation therapy treatment systems, both with
Volumetric Modulated Arc Therapy (VMAT). The first site in the world to have
both Elekta Axesse and Elekta Infinity, CentraState will offer the most advanced
cancer care available to its patients. 


CentraState Medical Center, a part of the CentraState Healthcare System,
currently is treating 45 to 50 patients a day - with fluctuations as high as 70
patients per day, all on one treatment unit. When the time came to add another
treatment system, CentraState elected to replace another manufacturer's system
and install two new Elekta systems. 

Jan Dragotta, Clinical Director, Radiation Oncology, says the decision process
took several months and involved a team of CentraState physicians, physicists
and administrators. 

“In order to determine which technologies, both standard and emerging, had the
most value, we completed a complex analysis to determine our current market and
potential for growth,” she said. “We all felt radiosurgery and motion management
were the areas we wanted to grow, and that was supported by The Advisory Board
Company in Washington D.C., which projected that, in the next 10 years, the
biggest growth in cancer treatment will occur in radiosurgery.”

One key determining factors in choosing Elekta was CentraState's desire to
partner with a company that would ensure the institution would remain ahead of
the technological curve. 

Robert Smith, MS, Director of Physics, says, “Elekta's reputation has grown in
recent years, so we spent a lot of time comparing Elekta with other systems, and
discovered that Elekta systems had many advantages over the competition,
especially in imaging capabilities. We decided to make the switch to Elekta.”  

“We'll be replacing our current IMRT techniques with VMAT,” he explains. “We're
looking to VMAT to increase throughput, but more importantly to reduce treatment
times for our patients. That, in turn, will reduce the chance of patient
movement during the treatment, another big concern, especially in lung and
abdomen applications. We feel we can deliver a better, more precise treatment to
the patient by delivering the dose in a shorter time.”

Edward Soffen, M.D., Medical Director, says, “VMAT is the newest, latest,
greatest technology for conforming the beam as closely as possible to the
target. Although we're doing a good job now sparing healthy tissue, we're taking
it to the next level of sophistication with VMAT. It's really advanced
technology that will force others to be competitive with us, in terms of
providing the most sophisticated technology available. We wanted the latest
tools that really hone in on the tumor, give us better image guidance, and are
compatible with our other hardware and software.”

The new Elekta systems will be installed in August 2010. “As a team, we've spent
a lot of time and effort evaluating treatment systems,” says Dr. Soffen, “and I
commend our administration for allowing us to have the best available tools to
treat our patients.”

“The management team at Elekta has a desire to develop clinically relevant
techniques, and we have found Elekta to be far more personable and approachable
than the other corporations,” adds Robert Smith. They will definitely work with
us to give our patients the best treatments possible.”

For the latest Elekta VMAT news, visit elekta.com/vmat.

For further information, please contact:

Stina Thorman, Investor Relations, Elekta AB
Tel: +46 8 587 254 37, +46 70 778 60 10, e-mail: lstina.thorman@elekta.com

 Michelle Lee, Director, Marketing Services, Elekta Inc. 
Tel: +1 770-670-2447, e-mail: michelle.lee@elekta.com




About Elekta

Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated state of the art tools and treatment planning systems for
radiation therapy and radiosurgery, as well as workflow enhancing software
systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives,
making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000
hospitals globally, and every day more than 100,000 patients receive diagnosis,
treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is
located in Stockholm, Sweden, and the company is listed on the Nordic Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.

About CentraState

CentraState Healthcare System is a non-profit community health organization
consisting of an acute-care hospital, an ambulatory care campus, three senior
living communities, a Family Medicine Residency Program, and a charitable
foundation. CentraState is a member of the Robert Wood Johnson Health Network
and a clinical research affiliate of The Cancer Institute of New Jersey, a
National Cancer Institute-designated Comprehensive Cancer Center.